Russia’s Sputnik V vaccine review in Europe stymied by data gaps

The Jerusalem Post


Sputnik V is marketed overseas by Russia’s sovereign wealth fund, called the Russian Direct Investment Fund (RDIF). RDIF said Reuters’ reporting contained “false and inaccurate statements” based on anonymous sources who are attempting to harm Sputnik V as part of a disinformation campaign. It added that Sputnik V has not been distributed to people in Brazil. The Slovakian government this month said it sold most of its Sputnik V back to Russia, citing low interest. Anvisa publicly said there was a risk the adenovirus in Sputnik V could replicate, potentially causing a negative reaction in recipients.


68.56% objective
51.42% positive